GlassScriptPhysician profile
Brooke Gabrielle Boswell
NPI 1275295644
$5,661.73
in general payments reported to CMS, 2019-2025
33 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,428 · 2023: $1,393 · 2024: $1,393 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,212.15 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $600.43 | 2022-2025 | |
| Lilly USA, LLC | $599.61 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $410.42 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $407.15 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.88 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $271.74 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $237.26 | 2022-2025 | Verquvo, Capvaxive, Belsomra |
| Pfizer INC. | $183.54 | 2024-2025 | |
| Exact Sciences Corporation | $165.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.74 | 2022-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $133.46 | 2022-2024 | |
| Glaxosmithkline, LLC. | $129.59 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $125.49 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $81.20 | 2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $71.43 | 2022-2023 | Austedo |
| Kowa Pharmaceuticals America, INC. | $66.64 | 2022 | |
| Corium, LLC | $52.75 | 2023 | Azstarys |
| Dexcom, INC. | $38.13 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $36.57 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $34.09 | 2024 | Gvoke Hypopen |
| Mylan Specialty L.P. | $32.61 | 2022-2023 | Yupelri |
| Atricure, INC. | $26.81 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.60 | 2022-2024 | Edarbyclor |
| Otsuka America Pharmaceutical, INC. | $21.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.61 | 2022 | |
| Abbott Laboratories | $20.32 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $18.60 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2022 | |
| Lundbeck LLC | $14.71 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $13.81 | 2023 | Aptima |
| Amarin Pharma, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.